Bioverativ Inc. (NASDAQ:BIVV) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) are both Healthcare companies that recently hit new low. Naturally, this has caught the attention of the investment community. But which is the better investment? To answer this question, we will compare the two companies across various metrics including growth, profitability, risk, return, dividends, and valuation.Bioverativ Inc. (NASDAQ:BIVV) operates in the Biotechnology segment of the Healthcare sector. BIVV has a net profit margin of 40.40% and is more profitable than the average company in the Biotechnology industry. Company’s return on equity, which is really just the product of the company’s profit margin, asset turnover, and financial leverage ratios, is 68.90%, which is better than the Biotechnology industry average ROE.Stock’s free cash flow yield, which represents the amount of cash available to investors before dividends, expressed as a percentage of the stock price, is 2.21. Company trades at a P/E ratio of 13.71 , and is less expensive than the average stock in the Biotechnology industry. The average investment recommendation for BIVV, taken from a group of Wall Street Analysts, is 2.30, or a buy.Over the past three months, Bioverativ Inc. insiders have been net buyers, dumping a net of -22 shares. This implies that insiders have been feeling relatively bearish about the outlook for BIVV. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) operates in the Biotechnology segment of the Healthcare sector. VRTX has increased sales at a 3.80% CAGR over the past five years, and is considered a low growth stock. The company has a net profit margin of 17.90% and is more profitable than the average Biotechnology player. VRTX’s asset turnover ratio is 0.74 and the company has financial leverage of 0.78. VRTX’s return on equity of 26.80% is better than the Biotechnology industry average.
     (adsbygoogle = window.adsbygoogle || []).push({});
Stock has a payout ratio of 0.00%. According to this ratio, VRTX should be able to continue making payouts at these levels. The company trades at a free cash flow yield of 0.39 and has a P/E of 188.99. Compared to the average company in the 197.02 space, VRTX is relatively cheap. The average analyst recommendation for VRTX is 1.80, or a buy.Vertex Pharmaceuticals Incorporated insiders have sold a net of -284,013 shares during the past three months, which implies that the company’s top executives have been feeling bearish about the stock’s outlook. Finally, VRTX’s beta of 1.61 indicates that the stock has an below average level of market risk.Bioverativ Inc. (NASDAQ:BIVV) scores higher than Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on 7 of the 13 measures compared between the two companies. BIVV has the better fundamentals, scoring higher on profitability, leverage and return metrics. BIVV wins on valuation measures. BIVV has better insider activity and sentiment signals.



(adsbygoogle = window.adsbygoogle || []).push({});




(adsbygoogle = window.adsbygoogle || []).push({});




(adsbygoogle = window.adsbygoogle || []).push({});


Economy and Money Authors gives investors their free and unbiased view of Financial Markets and on what happening in Stock Market. Our team certainly analyze tons of Stocks every day and provide their fair opinion on them. We are always looking over financial statements, company’s earning, analyst upgrades/downgrades, joint ventures and balance sheets to keep our reader up to date.